In an interview with Radio Goftogoo, Haji Moradi stated; “Razi vaccine can produce over 80% immunization in the 2nd phase, and in phase 3, it’s been proved 2.5 times more effective than Sinopharm.”
Dr. Monireh Haji Moradi, the faculty member of Razi Institute and the member of Razi Cov Pars vaccine research team had a phone call interview with "Scientific Dialogue" program regarding the effectiveness of Iranian vaccines against new variants of Corona virus.
Haji Moradi explained about Razi Cov Pars vaccine and said; “This vaccine received an emergency use license and 5 million doses were delivered to the Ministry of Health. Besides, we have a monthly production capacity of 5 million doses and we can deliver 20 million doses by December.”
She continued, “We could have produced even more doses, but due to the longer licensing process, the production process of this vaccine became longer.”
Razi Koopars, a member of the vaccine research team, said that stopping vaccination was not in the best interests at all: speeding up the process of licensing and supporting domestic vaccines would definitely be in the interest of the country and the health of the people; The available vaccines are less effective against the worrying strain of omicron, so it is strongly recommended that people receive a third dose of the vaccine.
Haji Moradi stated on Radio Goftogo that the Razi vaccine has been used as a booster dose: According to studies, the Razi vaccine is over 80% safe in phase 2, and in phase 3, it is 2.5 times more effective than Sinofarm. had. We also did not see any severe form and hospitalization and we are currently studying the booster dose.
Reporter: Farzaneh Moradi
